Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain (2012) 5.83

Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2008) 5.35

Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology (2013) 4.60

Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93

Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol (2008) 3.92

The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84

Interferon beta in multiple sclerosis. BMJ (1996) 3.80

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology (2011) 3.62

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ (2003) 3.31

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry (2002) 2.97

Evidence for a two-stage disability progression in multiple sclerosis. Brain (2010) 2.63

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58

A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology (2012) 2.46

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37

Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage (2006) 2.35

Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology (2010) 2.30

HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology (2010) 2.29

Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 2.23

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol (2015) 2.23

MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler (2010) 2.13

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11

Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials (2015) 2.11

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology (2009) 2.10

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol (2006) 2.06

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06

Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 2.03

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet (2003) 2.02

Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 2.01

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (1990) 1.99

Validation of the "World Health Organization Disability Assessment Schedule, WHODAS-2" in patients with chronic diseases. Health Qual Life Outcomes (2010) 1.94

Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol (2007) 1.92

Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium) J Neurol Neurosurg Psychiatry (1998) 1.90

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ (2004) 1.84

Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med (2008) 1.82

AQP4 antibody-positive Thai cases: clinical features and diagnostic problems. Neurology (2011) 1.77

Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry (2008) 1.77

Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol (2008) 1.75

Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75

Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ (2004) 1.74

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ (2003) 1.73

Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73

Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain (2003) 1.71

Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage (2010) 1.71

Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging (2009) 1.70

Community services in multiple sclerosis: still a matter of chance. J Neurol Neurosurg Psychiatry (2000) 1.68

Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology (2014) 1.65

Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology (2012) 1.65

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry (2002) 1.64

Clinical neurology: why this still matters in the 21st century. J Neurol Neurosurg Psychiatry (2014) 1.64

Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry (2002) 1.64

In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology (2009) 1.64

Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry (2006) 1.63

Multiparametric magnetic resonance imaging analysis of the corticospinal tract in multiple sclerosis. Neuroimage (2007) 1.62

Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry (2006) 1.61

T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology (2008) 1.59

Obstructive sleep apnea and fatigue in patients with multiple sclerosis. J Clin Sleep Med (2014) 1.59

A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging. Brain (2015) 1.59

In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology (2009) 1.58

Abnormal heart rate and blood pressure responses to baroreflex stimulation in multiple sclerosis patients. Clin Auton Res (2005) 1.58

Quantitative risk-benefit analysis of natalizumab. Neurology (2008) 1.58

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes (2008) 1.56

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.56

Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56

Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel index and the Functional Independence Measure. J Neurol Neurosurg Psychiatry (1999) 1.54

Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging (2007) 1.54

Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54

Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer (2010) 1.54

Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis: improving correlations with disability. J Neurol Neurosurg Psychiatry (2003) 1.53

Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.53

Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol (2013) 1.53

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A (2000) 1.53

Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol (2007) 1.51

CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A (2003) 1.51

Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry (2001) 1.51

A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry (2005) 1.50

Longitudinal relationships among posturography and gait measures in multiple sclerosis. Neurology (2015) 1.50

Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol (2014) 1.50

Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49

Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis. Neurology (2010) 1.48

Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder. J Neurol (2013) 1.48

Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother (2003) 1.47

Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am J Neuroradiol (2010) 1.47

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47

Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain (2015) 1.46

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2011) 1.46

Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45

The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis. Mediators Inflamm (1998) 1.45

Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed. Gait Posture (2012) 1.45

Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest (2008) 1.44

Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol (2009) 1.43

Motor network efficiency and disability in multiple sclerosis. Neurology (2015) 1.43

Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. J Neurol Neurosurg Psychiatry (2000) 1.43

Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation. PLoS One (2015) 1.42

Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy. J Clin Immunol (2000) 1.42

Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study. J Neurol Sci (2009) 1.41

Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry (1994) 1.41

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med (1992) 9.71

The current neurologic burden of illness and injury in the United States. Neurology (1982) 3.41

On the risk of multiple sclerosis according to age at immigration to South Africa. Br Med J (1971) 3.17

Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report. Neurology (1970) 2.56

Diagnostic criteria for the Guillain-Barré syndrome. An analysis of 50 cases. J Neurol Sci (1971) 2.39

Studies on the natural history of multiple sclerosis. 3. Epidemiologic analysis of the army experience in World War II. Neurology (1967) 2.09

Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology (1979) 2.07

Multiple sclerosis in the Faroe Islands: I. Clinical and epidemiological features. Ann Neurol (1979) 1.95

A reassessment of the distribution of multiple sclerosis. Part one. Acta Neurol Scand (1975) 1.81

Neuroepidemiology. Ann Neurol (1984) 1.67

Epidemiology of amyotrophic lateral sclerosis: 1. A case-control comparison based on ALS deaths. Neurology (1980) 1.60

Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. Arch Neurol (1970) 1.52

Geographic distribution of multiple sclerosis: An update with special reference to Europe and the Mediterranean region. Acta Neurol Scand (1980) 1.47

On national needs for neurologists in the United States. Neurology (1986) 1.44

Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurol Scand (1970) 1.40

Multiple sclerosis in the Faroe Islands. 8. Notifiable diseases. Acta Neurol Scand (2009) 1.39

A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand (1975) 1.36

Studies on the natural history of multiple sclerosis. 2. The progression of optic neuritis to multiple sclerosis. Acta Neurol Scand (1966) 1.32

Mortality and migration in multiple sclerosis. Neurology (1971) 1.32

Multiple sclerosis in Iceland: 1. Evidence of a postwar epidemic. Neurology (1982) 1.31

Epidemiologic contributions to multiple sclerosis: an overview. Neurology (1980) 1.28

Geography in multiple sclerosis. J Neurol (1977) 1.26

Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness. J Chronic Dis (1977) 1.23

A method for estimating the age at immigration of white immigrants to South Africa, with an example of its importance. S Afr Med J (1970) 1.19

Multiple sclerosis and infection from an epidemiologic aspect. Neurology (1968) 1.18

Trauma-induced intention tremor relieved by stereotaxic thalamotomy. Arch Neurol (1966) 1.14

Survival in multiple sclerosis. J Clin Epidemiol (1989) 1.13

Prevalence of multiple sclerosis in the Parsis of Bombay. Neurology (1988) 1.09

On the fine structure of the distribution of multiple sclerosis. Acta Neurol Scand (1967) 1.07

Neurologists in the United States--past, present, and future. Neurology (1986) 1.07

Comparison of clinic, home, and deferred language treatment for aphasia. A Veterans Administration Cooperative Study. Arch Neurol (1986) 1.07

Epidemiology of spinal cord injury. Exp Neurol (1975) 1.05

Multiple sclerosis: an epidemic disease in the Faeroes. Trans Am Neurol Assoc (1975) 1.02

Multiple sclerosis in the Faroe Islands. II. Clinical update, transmission, and the nature of MS. Neurology (1986) 1.02

Epidemiology of myasthenia gravis. Adv Neurol (1978) 1.00

Unsuccessful attempt to induce transformation by cerebrospinal fluid in cultured lymphocytes from patients with multiple sclerosis. N Engl J Med (1968) 1.00

Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis. Neurology (1987) 0.99

An epidemiologic approach to multiple sclerosis. Arch Neurol (1966) 0.99

Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. J Chronic Dis (1983) 0.99

Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology (1985) 0.98

Virus antibodies and multiple sclerosis. Arch Neurol (1971) 0.98

Twin study of multiple sclerosis: an epidemiologic inquiry. Neurology (1978) 0.97

Neuroepidemiology. Part II: Assessment of therapeutic trials. Ann Neurol (1986) 0.97

An evaluation of the geographic distribution of multiple sclerosis. Acta Neurol Scand (1966) 0.97

Disability rating scales in multiple sclerosis. Ann N Y Acad Sci (1984) 0.96

Optic neuritis or multiple sclerosis. Arch Neurol (1985) 0.96

Cooperative study in the evaluation of therapy in multiple sclerosis; ACTH vs placebo in acute exacerbations. Preliminary report. Neurology (1968) 0.95

Posterior communicating artery giant aneurysm as a cause of seizures. Neurology (1985) 0.95

Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution? Neurol Sci (2000) 0.95

Glioblastoma multiforme involving the posterior fossa. Case report and review of literature. Dis Nerv Syst (1966) 0.95

Veterans Administration cooperative study on aphasia: a comparison of individual and group treatment. J Speech Hear Res (1981) 0.95

Studies on natural history of multiple sclerosis. 4. Clinical features of the onset bout. Acta Neurol Scand (1968) 0.94

Multiple sclerosis among immigrants. Br Med J (1976) 0.93

Myorhythmia: a widespread movement disorder. Clinicopathological correlations. Brain (1984) 0.92

On statistical testing of prevalence studies. J Chronic Dis (1966) 0.91

Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain (2000) 0.91

Studies on the natural history of multiple sclerosis. 7. Correlates of clinical change in an early bout. Acta Neurol Scand (1973) 0.90

Cerebral mucormycosis (Phycomycosis) in a heroin addict. Arch Neurol (1982) 0.89

Studies on the natural history of multiple sclerosis. 6. Clinical and laboratory findings at first diagnosis. Acta Neurol Scand (1972) 0.88

Epidemiology of multiple sclerosis in U.S. veterans: V. Ancestry and the risk of multiple sclerosis. Ann Neurol (1993) 0.86

The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology (1979) 0.86

The course of alcoholic-nutritional peripheral neuropathy. Acta Neurol Scand (1982) 0.86

In defense of death data: an example with multiple sclerosis. Neurology (1985) 0.86

Epidemiology of amyotrophic lateral sclerosis. Adv Neurol (1982) 0.85

Multiple sclerosis: changing times. Neuroepidemiology (1991) 0.85

Further considerations on the geographic distribution of multiple sclerosis. Acta Neurol Scand (1967) 0.84

An assessment of the reliability of three methods used in evaluating the status of multiple sclerosis patients. J Chronic Dis (1969) 0.84

Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration. J Neurol (2011) 0.84

Epidemiology of spinal cord injury. Neurol Neurocir Psiquiatr (1977) 0.83

Bilateral ballism in multiple sclerosis. Neurology (1989) 0.83

Ocular dipping. Neurology (1984) 0.83

Periodic alternating ping-pong gaze. Ann Ophthalmol (1981) 0.82

Spinal cord ataxia. Neurology (1993) 0.81

Multiple sclerosis in a migrant population: 2. Half-orientals immigrating in childhood. Ann Neurol (1980) 0.81

Delayed dermal hypersensitivity to measles and mumps antigens among multiple sclerosis and control patients. Neurology (1969) 0.81

Medical facilities and the prevalence of multiple sclerosis. Acta Neurol Scand (1965) 0.80

Geographic distribution of brain tumors. Trans Am Neurol Assoc (1967) 0.80

Survival in multiple sclerosis. Trans Am Neurol Assoc (1969) 0.80

Plasmapheresis in Guillain-Barré syndrome. Neurology (1985) 0.80

MR vs CT in progressive supranuclear palsy. Comput Med Imaging Graph (1996) 0.80

Diagnosis and differential diagnosis of multiple sclerosis. Acta Neurol Scand (1970) 0.79

Epidemiology of multiple sclerosis in US veterans. 6. Population ancestry and surname ethnicity as risk factors for multiple sclerosis. Neuroepidemiology (1995) 0.79

Geographic pathology of brain tumors. 1. Distribution of deaths from primary tumors. Acta Neurol Scand (1969) 0.79

Motor neuron(e) disease. Br Med J (Clin Res Ed) (1982) 0.79

Downbeat nystagmus secondary to multiple sclerosis. Ann Ophthalmol (1988) 0.78

Home treatment for aphasic patients by trained nonprofessionals. J Speech Hear Disord (1989) 0.78

Some epidemiologic features compatible with an infectious origin for multiple sclerosis. Int Arch Allergy Appl Immunol (1969) 0.78

MS epidemiology in Faroe Islands. Riv Neurol (1987) 0.78

Dogs, distemper, and multiple sclerosis in the United States. Acta Neurol Scand (1979) 0.77

Further considerations on the distribution of multiple sclerosis in Sweden. Acta Neurol Scand (2005) 0.77

Multiple sclerosis in Korea. Clinical features and prevalence. J Neurol Sci (1969) 0.77

Migration and multiple sclerosis in United Kingdom and Ireland immigrants to Australia: a reassessment. II. Characteristics of early (pre-1947) compared to later migrants. J Neurol (2011) 0.77

ICD 9: a regression. Am J Epidemiol (1979) 0.76

Multiple sclerosis death rates from underlying cause and total deaths. Acta Neurol Scand (1972) 0.76

Caveat computator. Methods Inf Med (1967) 0.76

The risk of multiple sclerosis in Denmark. Acta Neurol Scand (1978) 0.76

Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo in acute exacerbation. Trans Am Neurol Assoc (1969) 0.76

Further features of the Fennoscandian focus of multiple sclerosis. Acta Neurol Scand (1974) 0.76

A critical age for the acquisition of multiple sclerosis. Trans Am Neurol Assoc (1970) 0.76

Studies on the natural history of multiple sclerosis. 1. Design and diagnosis. Acta Neurol Scand (1966) 0.76